The Institute of Cancer Research (ICR; London, UK) recently announced the results of the landmark PROfound trial investigating the use of olaparib in prostate cancers with faulty DNA repair genes. Researchers from the ICR and Royal Marsden NHS Trust (London, UK) observed that the PARP inhibitor significantly reduced tumor growth and improved overall survival, demonstrating greater efficacy compared with existing hormone therapies.
The results, recently published in the New England Journal of Medicine, are set to herald the landmark approval of olaparib (Lynparza®) for use in prostate cancers with DNA repair pathway mutations. The study compared the treatment against current standard-of-care hormone therapies, abiraterone (Zytiga®) and enzalutamide (Xtandi®).
To view the full article, please register now for access